H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Atai Life Sciences (ATAI) to $15 from $10 and keeps a Buy rating on the shares. The firm remains bullish on Atai despite the Phase 2b trial evaluating inidascamine in patients with cognitive impairment associated with schizophrenia missing the primary endpoint. In a follow-up call, management reiterated the company focus on the company’s wholly-owned psychedelics pipeline, including BPL-003, which has continued to exceed expectations, the analyst tells investors in a research note. H.C. Wainwright cites Atai’s focus on its “most promising near-term asset” for the target increase.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Sarepta upgraded, Tapestry downgraded: Wall Street’s top analyst calls
- Atai Life Sciences initiated with an Outperform at Oppenheimer
- Morning Movers: Venture Global and Cheniere rise following U.S.-EU trade deal
- ATAI Life Sciences: Strategic Focus on BPL-003 Amid Setbacks Offers Investment Opportunity
- Atai Life Sciences price target lowered to $11 from $12 at Canaccord